GlassScriptPhysician profile
Sara A Olson
NPI 1255589883
$5,498.69
in general payments reported to CMS, 2019-2025
44 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,502 · 2022: $1,172 · 2023: $1,337 · 2024: $867 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,825.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.54 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $587.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $359.04 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $299.20 | 2021-2025 | Farxiga, Fasenra |
| Inspire Medical Systems, INC. | $281.28 | 2023-2024 | Inspire |
| Esperion Therapeutics, INC. | $268.80 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $218.45 | 2021-2023 | Xarelto |
| Amgen INC. | $217.92 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $200.52 | 2021-2024 | |
| Seqirus USA INC | $145.45 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Glaxosmithkline, LLC. | $134.17 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $119.18 | 2021-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $92.21 | 2022 | |
| Merck Sharp & Dohme LLC | $87.53 | 2021-2023 | Pneumovax 23, Vaxelis, Vaxneuvance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.